Byoung Chul Cho, MD

Professor Byoung Chul Cho, MD, PhD
 

Yonsei Cancer Center
Yonsei University College of Medicine J
JE-UK Laboratory of Molecular Cancer Therapeutics
Seoul, Korea

What genomic alterations (i.e. driver events) does the NCCN identify for non-small cell lung cancer (NSCLC)? And what targeted agents does the NCCN recommend for these specific driver events? Video

What genomic alterations (i.e. driver events) does the NCCN identify for non-small cell lung cancer (NSCLC)? And what targeted agents does the NCCN recommend for these specific driver events?

What genomic alterations (i.e. driver events) does the NCCN identify for non-small cell lung cancer (NSCLC)? And what targeted agents does the NCCN recommend for these specific driver events?
Professor Byoung Chul Cho, MD, PhD

Professor Byoung Chul Cho, MD, PhD

Based on clinical data and FDA approvals, why do NCCN guidelines for NSCLC recommend erlotinib and gefitinib as first-line systemic therapy in patients with sensitizing EGFR mutations? Video

Based on clinical data and FDA approvals, why do NCCN guidelines for NSCLC recommend erlotinib and gefitinib as first-line systemic therapy in patients with sensitizing EGFR mutations?

Based on published clinical data and FDA approvals, why do NCCN guidelines for NSCLC recommend erlotinib and gefitinib as recommended (category 1) first-line systemic therapy in patients with sensitizing EGFR mutations?
Professor Byoung Chul Cho, MD, PhD

Professor Byoung Chul Cho, MD, PhD

In what kind of solid tumors can comprehensive genomic profiling/NGS make a difference in identifying patients with EGFR and other mutations that may be missed by hotspot tests? (Korean) Video

In what kind of solid tumors can comprehensive genomic profiling/NGS make a difference in identifying patients with EGFR and other mutations that may be missed by hotspot tests? (Korean)

In what kind of solid tumors, specifically NSCLC, can comprehensive genomic profiling/NGS make a difference in identifying patients with EGFR and other mutations—ALK, MET, ROS-1—that may be missed by hotspot tests?
Professor Byoung Chul Cho, MD, PhD

Professor Byoung Chul Cho, MD, PhD

What is the importance of the gene encoding the ROS1 proto-oncogene receptor tyrosine kinase as a distinct molecular subgroup of NSCLC? In what percentage of patients is ROS1 detected? Video

What is the importance of the gene encoding the ROS1 proto-oncogene receptor tyrosine kinase as a distinct molecular subgroup of NSCLC? In what percentage of patients is ROS1 detected?

What is the importance of the gene encoding the ROS1 proto-oncogene receptor tyrosine kinase (ROS1) as a distinct molecular subgroup of NSCLC? In what percentage of patients is ROS1 detected?
Professor Byoung Chul Cho, MD, PhD

Professor Byoung Chul Cho, MD, PhD

What is the importance of NGS for finding EGFR sensitizing mutations such as exon 19 or exon 21 in NSCLC? What is their relationship to sensitivity to TKIs, such as erlotinib, gefitinib, and afatinib? Video

What is the importance of NGS for finding EGFR sensitizing mutations such as exon 19 or exon 21 in NSCLC? What is their relationship to sensitivity to TKIs, such as erlotinib, gefitinib, and afatinib?

What is the importance of NGS for finding EGFR sensitizing mutations such as exon 19 or exon 21 in NSCLC? What is their relationship to sensitivity to TKIs, such as erlotinib, gefitinib, and afatinib?
Professor Byoung Chul Cho, MD, PhD

Professor Byoung Chul Cho, MD, PhD